Is Zepbound a pill?
No, Zepbound is not a pill. It is tirzepatide, an injectable medication approved by the FDA for chronic weight management in adults with obesity or overweight conditions with related health issues. It comes as a weekly subcutaneous injection using a prefilled, single-dose pen.[1]
How is Zepbound administered?
Patients self-administer Zepbound once weekly into the abdomen, thigh, or upper arm. Doses start at 2.5 mg and increase gradually to a maximum of 15 mg, based on tolerance and response. It requires refrigeration and is not available as an oral tablet.[1][2]
Why isn't Zepbound available as a pill?
Tirzepatide is a peptide-based GLP-1/GIP receptor agonist that must be injected because oral forms degrade in the stomach due to digestive enzymes and poor absorption. Eli Lilly has focused on the injectable version for efficacy, though they are developing oral GLP-1 drugs like orforglipron in clinical trials.[2][3]
Does Zepbound have an oral version or alternative?
No oral Zepbound exists or is approved. An investigational oral tirzepatide is in early trials, but no timeline for approval. For oral weight loss options, patients turn to pills like phentermine or semaglutide alternatives, though none match Zepbound's dual GLP-1/GIP mechanism.[3]
How does Zepbound compare to oral weight loss drugs?
Unlike daily pills such as Wegovy (semaglutide injection, not pill) or older orals like Qsymia, Zepbound offers superior weight loss—up to 21% body weight reduction in trials—due to its dual action. Oral drugs typically yield 5-10% loss with more side effects like insomnia.[1][2]
What are common patient concerns with Zepbound injections?
Many ask about needle phobia or ease of use; the pen is auto-injector style, similar to insulin pens, with minimal training needed. Side effects include nausea, diarrhea, and injection-site reactions, often improving over time.[1]
[1]: FDA Label for Zepbound
[2]: Eli Lilly Zepbound Prescribing Information
[3]: DrugPatentWatch.com - Tirzepatide Patents